整合素α7与肿瘤关系的研究进展

doi:10.3969/j.issn.1004-616x.2020.04.013

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (4): 317-320,324.doi: 10.3969/j.issn.1004-616x.2020.04.013

整合素α7与肿瘤关系的研究进展

张西德^1,3, 倪豪^1,3, 陆文博^1,3, 徐莎^1,2, 熊俊¹

1. 海军军医大学基础医学院组织胚胎学教研室, 上海 200433;
2. 海军军医大学转化医学研究中心, 上海 200433;
3. 海军军医大学基础医学院学员十二队, 上海 200433

收稿日期:2019-07-29 修回日期:2020-05-10 出版日期:2020-07-31 发布日期:2020-08-01
通讯作者: 熊俊,xiongjun2001@163.com E-mail:xiongjun2001@163.com
作者简介:张西德,E-mail:zxd123852@163.com。
基金资助:
国家自然科学基金（81600113）；中国博士后科学基金（2016M593007）

Received:2019-07-29 Revised:2020-05-10 Online:2020-07-31 Published:2020-08-01

摘要/Abstract

摘要： 整合素α7与整合素β1结合形成α7β1异二聚体复合体，通过与细胞外基质中的层黏连蛋白结合，介导细胞与细胞、细胞与细胞外基质间的相互黏附，并将细胞外信号传导至细胞内，使细胞维持稳定或作出相应的反应。整合素α7蛋白最早在黑色素瘤细胞中被鉴定出来，后续研究表明整合素α7在骨骼肌和肠道细胞正常发育和功能维持中有重要作用。近年来越来越多的研究发现整合素α7在多种肿瘤进程中扮演了重要角色，包括调节细胞增殖和凋亡、迁移和侵袭、上皮间充质转化、干细胞特性维持等细胞生物学行为。本文就整合素α7的结构和功能，以及其在肿瘤，包括胶质母细胞瘤、食管鳞状细胞癌、肝细胞癌、结直肠癌、乳腺癌、前列腺癌和间皮瘤中的作用和作用机制的研究进展作一综述。

关键词: 肿瘤, 整合素, 整合素α7, 层黏连蛋白, 受体

中图分类号:

R730.2

张西德, 倪豪, 陆文博, 徐莎, 熊俊. 整合素α7与肿瘤关系的研究进展[J]. 癌变·畸变·突变, 2020, 32(4): 317-320,324.

参考文献

[1] DESGROSELLIER J S, CHERESH D A. Integrins in cancer:biological implications and therapeutic opportunities[J]. Nat Rev Cancer, 2010, 10(1):9-22.
[2] SEGUIN L, DESGROSELLIER J S, WEIS S M, et al. Integrins and cancer:regulators of cancer stemness, metastasis, and drug resistance[J]. Trends Cell Biol, 2015, 25(4):234-240.
[3] BARCZYK M, CARRACEDO S, GULLBERG D. Integrins[J]. Cell Tissue Res, 2010, 339(1):269-280.
[4] BASORA N, VACHON P H, HERRING-GILLAM F E, et al. Relation between integrin alpha7Bbeta1 expression in human intestinal cells and enterocytic differentiation[J]. Gastroenterology, 1997, 113(5):1510-1521.
[5] BURKIN D J, KAUFMAN S J. The alpha7beta1 integrin in muscle development and disease[J]. Cell Tissue Res, 1999, 296(1):183-190.
[6] KRAMER R H, VU M P, CHENG Y F, et al. Laminin-binding integrin alpha 7 beta 1:functional characterization and expression in normal and malignant melanocytes[J]. Cell Regul, 1991, 2(10):805-817.
[7] WANG W, WU W, DESAI T, et al. Localization of the alpha 7 integrin gene (ITGA7) on human chromosome 12q13:clustering of integrin and Hox genes implies parallel evolution of these gene families[J]. Genomics, 1995, 26(3):568-570.
[8] GANGULY K K, PAL S, MOULIK S, et al. Integrins and metastasis[J]. Cell Adhesion Migr, 2013, 7(3):251-261.
[9] VIGNIER N, MOGHADASZADEH B, GARY F, et al. Structure, genetic localization, and identification of the cardiac and skeletal muscle transcripts of the human integrin alpha7 gene (ITGA7)[J]. Biochem Biophys Res Commun, 1999, 260(2):357-364.
[10] LI X M, WANG J J, ZHANG C, et al. Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7[J]. J Pathol, 2018, 246(2):166-179.
[11] YANG G P, ZHANG T H, YE J N, et al. Circ-ITGA7 sponges miR-3187-3p to upregulate ASXL1, suppressing colorectal cancer proliferation[J]. Cancer Manag Res, 2019, 11:6499-6509.
[12] GAWLIK K I, MAYER U, BLOMBERG K, et al. Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan[J]. FEBS Lett, 2006, 580(7):1759-1765.
[13] HAAS T L, SCIUTO M R, BRUNETTO L, et al. Integrin α7 is a functional marker and potential therapeutic target in glioblastoma[J]. Cell Stem Cell, 2017, 21(1):35-50.e9.
[14] NIXON A M L, DUQUE A, YELLE N, et al. A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations[J]. Sci Rep, 2019, 9(1):842.
[15] MING X Y, FU L, ZHANG L Y, et al. Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma[J]. Nat Commun, 2016, 7:13568.
[16] SU Y, GUAN X Q, LIU F Q, et al. The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells[J]. Int J Mol Med, 2014, 34(3):842-848.
[17] ULISSE S, BALDINI E, SORRENTI S, et al. The urokinase plasminogen activator system:a target for anti-cancer therapy[J]. Curr Cancer Drug Targets, 2009, 9(1):32-71.
[18] ZHANG Y R, TAO X M, JIN G Z, et al. A targetable molecular chaperone Hsp27 confers aggressiveness in hepatocellular carcinoma[J]. Theranostics, 2016, 6(4):558-570.
[19] CHIBA T, YOKOSUKA O, FUKAI K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells[J]. Oncology, 2004, 66(6):481-491.
[20] LIU J, ZHANG Z, LI X W, et al. Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression[J]. Oncogene, 2018, 37(41):5477-5491.
[21] BHANDARI A, XIA E J, ZHOU Y Y, et al. ITGA7 functions as a tumor suppressor and regulates migration and invasion in breast cancer[J]. Cancer Manag Res, 2018, 10:969-976.
[22] HUNG C M, KUO D H, CHOU C H, et al. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells[J]. J Agric Food Chem, 2011, 59(17):9683-9690.
[23] YUAN Z Y, DAI T, WANG S S, et al. Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis[J]. Onco Targets Ther, 2014, 7:1733-1742.
[24] DRIVALOS A, CHRISOFOS M, EFSTATHIOU E, et al. Expression of α 5-integrin, α7-integrin, E-cadherin, and N-cadherin in localized prostate cancer[J]. Urol Oncol, 2016, 34(4):165.e11-165.e18.
[25] TAN L Z, SONG Y, NELSON J, et al. Integrin α7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells[J]. Am J Pathol, 2013, 183(3):831-840.
[26] ZHU Z H, YU Y P, ZHENG Z L, et al. Integrin alpha 7 interacts with high temperature requirement A2(HtrA2) to induce prostate cancer cell death[J]. Am J Pathol, 2010, 177(3):1176-1186.
[27] HAN Y C, YU Y P, NELSON J, et al. Interaction of integrin-linked kinase and miniature chromosome maintenance 7-mediating integrin {alpha}7 induced cell growth suppression[J]. Cancer Res, 2010, 70(11):4375-4384.
[28] LASZLO V, HODA M A, GARAY T, et al. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma[J]. J Pathol, 2015, 237(2):203-214.
[29] BURKIN D J, FONTELONGA T M. Mesothelioma cells breaking bad:loss of integrin α7 promotes cell motility and poor clinical outcomes in patients[J]. J Pathol, 2015, 237(3):282-284.

整合素α7与肿瘤关系的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[2]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[3]	刘宁, 梁兰兰, 李淑芳, 沈祥春, 梁冰. 氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用[J]. 癌变·畸变·突变, 2021, 33(6): 426-429,434.
[4]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[5]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[6]	孙惠昕, 张茂祥, 王婉莹, 贾海晗, 宋冰冰. 2013—2017年黑龙江省肿瘤登记地区前列腺癌发病死亡情况及趋势分析[J]. 癌变·畸变·突变, 2021, 33(5): 345-348.
[7]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[8]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[9]	曾卓颖, 吴德生, 鲁晶晶, 廖慧, 赖洪飘, 袁建辉, 胡章立. 雌激素受体α介导氧化磷酸化通路在肺癌发生中的作用[J]. 癌变·畸变·突变, 2021, 33(4): 262-268.
[10]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[11]	黄晓华, 牛永东, 石刚刚. 核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制[J]. 癌变·畸变·突变, 2021, 33(4): 302-306.
[12]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[13]	范玉宏, 周海丰, 范爽, 王立坤, 侯雅雄, 刘博. CXCR-2在食管鳞癌组织中的表达及其与MMP-9、VEGF的相关性研究[J]. 癌变·畸变·突变, 2021, 33(3): 225-229,240.
[14]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[15]	崔昭阳, 李素娜, 姜旭倩, 王弈丹, 侯丽颖. 芹菜素激活TRAIL死亡受体参与诱导胃癌SGC-7901细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 32-36.